Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right?

Affiliations

¹ Department of Radiotherapy of Oncology, University of Frankfurt, Frankfurt 60590, Germany; German Cancer Research Center, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany. Electronic address: emmanouil.fokas@kgu.de.
² Department of Radiotherapy of Oncology, University of Frankfurt, Frankfurt 60590, Germany; German Cancer Research Center, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany.
³ Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium; International Drug Development Institute, San Francisco, CA, USA.
⁵ Department of Radiotherapy, Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, UK.

Emmanouil Fokas et al. Lancet Gastroenterol Hepatol. 2023 Nov.

. 2023 Nov;8(11):962-964.

doi: 10.1016/S2468-1253(23)00231-5. Epub 2023 Aug 22.

¹ Department of Radiotherapy of Oncology, University of Frankfurt, Frankfurt 60590, Germany; German Cancer Research Center, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany. Electronic address: emmanouil.fokas@kgu.de.
² Department of Radiotherapy of Oncology, University of Frankfurt, Frankfurt 60590, Germany; German Cancer Research Center, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany.
³ Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Diepenbeek, Belgium; International Drug Development Institute, San Francisco, CA, USA.
⁵ Department of Radiotherapy, Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, UK.

No abstract available

LinkOut - more resources